The use of pharmaceuticals for colon cancer treatment has been increasingly personalized, in part due to the development of new molecular tools. In this review, we discuss the old and new colon cancer chemotherapeutics, and the parameters that have been shown to be predictive of efficacy and safety of these chemotherapeutics. In addition, we discuss how alternate pharmaceuticals have been developed in light of a potential lack of response or resistance to a particular chemotherapeutic. © 2013 by the authors; licensee MDPI, Basel, Switzerland.
CITATION STYLE
Kline, C. L. B., & El-Deiry, W. S. (2013). Personalizing colon cancer therapeutics: Targeting old and new mechanisms of action. Pharmaceuticals. MDPI AG. https://doi.org/10.3390/ph6080988
Mendeley helps you to discover research relevant for your work.